Biodegradable rapamycin-eluting nano-fiber membrane-covered metal stent placement to reduce fibroblast proliferation in experimental stricture in a canine model

Background and study aims: The aim of the current study was to assess whether placement of the biodegradable rapamycin-eluting nano-fiber membrane-covered metal stent is followed by less fibroblast proliferation and tissue hyperplasia compared with bare stents in experimental stricture in a dog model.

Methods: A total of 80 dog models of stricture were randomly divided into a control group (n = 20, no stent insertion), a bare stent group (BSG, n = 20, 1-week retention), and two drug-eluting stent sub-groups (DESG-1w, n = 20, 1-week retention; DESG-4w, n = 20, 4-week retention). Lower esophageal sphincter (LES) pressure, 5-minute barium height (5-mBH), and cardia diameter were assessed before, immediately after the procedure, and regularly thereafter for 6 months. Five dogs in each group were euthanized for histological examination at each follow-up assessment.

Results: Stent insertion was well tolerated, with similar migration rates (0 % in BSG vs. 7.5 % in DESGs; P = 0.5441). At 6 months, LES pressure and 5-mBH improved in DESG-1w (26.70 ± 5.02 mmHg and 6.50 ± 2.98 cm) and DESG-4w (20.16 ± 5.50 mmHg and 1.54 ± 0.98 cm) compared with BSG (39.94 ± 5.22 mmHg and 11.1 ± 5.46 cm) (P < 0.05), with DESG-4w being more stable than DESG-1w (P < 0.05). The cardia maintained greater patency in the DESGs (7.10 ± 3.09 mm in DESG-1w; 9.16 ± 3.77 mm in DESG-4w) than in the BSG (1.86 ± 2.45 mm; P < 0.05). Reduced peak inflammatory reactions and scarring occurred in DESGs compared with the BSG (P < 0.05), with a better outcome in DESG-4w than in DESG-1w (P < 0.05).

Conclusions: In this experimental stricture model, rapamycin-eluting stents were more effective than bare stents for the reduction of fibroblast proliferation and tissue hyperplasia after stent placement. Furthermore, 4-week retention of the drug-eluting stent led to a better outcome than 1-week retention.

• References

• 1 Ferguson DD. Evaluation and management of benign esophageal strictures. Dis Esophagus 2005; 18: 359-364
• 2 Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol 2005; 100: 1404-1414
• 3 Zhu YQ, Cheng YS, Tang GY et al. Comparison of temporary stent insertion with pneumatic dilation of the same diameter in the treatment of achalasia patients: a retrospective study. J Gastroenterol Hepatol 2010; 25: 499-505
• 4 Zhao JG, Li YD, Cheng YS et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience. Eur Radiol 2009; 19: 1973-1980
• 5 Zhu YQ, Cheng YS, Li MH et al. Temporary self-expanding cardia stents for the treatment of achalasia: an experimental study in dogs. Neurogastroenterol Motil 2010; 22: 1240-1247 , e321-322
• 6 Zilberman M, Eberhart RC. Drug-eluting bioresorbable stents for various applications. Annu Rev Biomed Eng 2006; 8: 153-180
• 7 Alexis F, Venkatraman SS, Rath SK et al. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Release 2004; 98: 67-74
• 8 Doggrell SA. Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery. Expert Opin Pharmacother 2004; 5: 1431-1434
• 9 Corbett SJ, Babic R, Cosgrave J et al. Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents. Cardiovasc Revasc Med 2006; 7: 159-164
• 10 Vakil N, Kadakia S, Eckardt VF. Pneumatic dilation in achalasia. Endoscopy 2003; 35: 526-530
• 11 Richardson WS, Willis GW, Smith JW. Evaluation of scar formation after botulinum toxin injection or forced balloon dilation to the lower esophageal sphincter. Surg Endosc 2003; 17: 696-698
• 12 Piotet E, Escher A, Monnier P. Esophageal and pharyngeal strictures: report on 1,862 endoscopic dilatations using the Savary–Gilliard technique. Eur Arch Otorhinolaryngol 2008; 265: 357-364
• 13 Cui WG, Zhou Y, Chang J. Electrospun nanofibrous materials for tissue engineering and drug delivery. Sci Technol Adv Mater 2010; 11: 014108
• 14 Zhu YQ, Cheng YS, Li F et al. Application of the newly developed stents in the treatment of benign cardia stricture: an experimental comparative study. Gastrointest Endosc 2011; 73: 329-337
• 15 Gaumnitz EA, Bass P, Osinski MA et al. Electrophysiological and pharmacological responses of chronically denervated lower esophageal sphincter of the opossum. Gastroenterology 1995; 109: 789-799
• 16 Singaram C, Sweet MA, Gaumnitz EA et al. Evaluation of early events in the creation of amyenteric opossum model of achalasia. Neurogastroenterol Motil 1996; 8: 351-361
• 17 Otsuka Y, Chronos NA, Apkarian RP et al. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher Stents. J Invasive Cardiol 2007; 19: 71-76
• 18 Xie CY, Li XH, Luo XM et al. Release modulation and cytotoxicity of hydroxycamptothecin-loaded electrospun fibers with 2-hydroxypropyl-cyclodextrin inoculations. Int J Pharm 2010; 391: 55-64
• 19 Kim HS, Yoo HS. MMPs-responsive release of DNA from electrospun nanofibrous matrix for local gene therapy: in vitro and in vivo evaluation. J Control Release 2010; 145: 264-271
• 20 Saraf A, Baggett LS, Raphael RM et al. Regulated non-viral gene delivery from coaxial electrospun fiber mesh scaffolds. J Control Release 2010; 143: 95-103
• 21 Seong H, An TK, Khang G et al. BCNU loaded poly(d,l-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm 2003; 251: 1-12
• 22 Ritger PL, Peppas NA. A simple equation for description of solute release. I. Fickean and non-Fickean release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 1987; 5: 23-36
• 23 Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181-1193
• 24 Morice MC, Serruys PW, Sousa JE et al. RAVEL study group, a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780
• 25 Regar E, Serruys PW, Bode C et al. Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx velocity balloon-expandable stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106: 1949-1956